RTG Represents AlloCyte in Acquisition of Tampa Area Bio-Manufacturing Facility

AlloCyte, LLC has acquired a 24,560-square-foot industrial property in Palm Harbor for $4.2 million.  The facility will support expanded operations for two life science companies in the Tampa Bay area – AlloCyte, which plans to be a worldwide manufacturer of the liquids that preserve organs for transplantation, and 34 Lives, PBC, which rescues unused kidneys for transplantation.

Located at 3816 DeSoto Blvd., the Palm Harbor property aligns the objectives of both AlloCyte and 34 Lives. Chris Jaynes, CEO of 34 Lives, highlights the strategic importance of the location due to the concentration of transplant hospitals in Florida. The first-floor manufacturing capabilities meet AlloCyte’s bio-manufacturing needs, and the existing ‘clean rooms’ on the upper floor fulfill sanitation requirements for 34 Lives. AlloCyte’s expansion plans include hiring 25 to 30 individuals for manufacturing roles, including personnel with medical and surgical expertise.

Realty Trust Group (RTG) represented AlloCyte in the acquisition of the facility and coordinated facility assessment and other due diligence efforts under a compressed timeline. RTG will be assisting in post-acquisition services including project management services to support the redevelopment of the facility and advisory support regarding pursuit of local economic incentives.

“We are honored to support Allocyte in the opening of their Tampa-based bio-manufacturing facility,” said RTG’s Jessica Gould. “Their presence will fill a gap in the Central Florida healthcare ecosystem and make a life-saving difference to transplant patients and families nationwide.”

For further details on the Palm Harbor building acquisition and the innovative strides made by AlloCyte and 34 Lives, refer to the original article: Palm Harbor Building Sold To Life Science Entrepreneurs For $4.2 Million.

For inquiries about RTG’s comprehensive services and support, please contact us here.